Brief: Grand Pharmaceutical Says NDA Of Ryaltris Submitted To Nmpa Accepted
08/02/2024 11:40
Feb 8 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* NDA OF GLOBAL INNOVATIVE PRODUCT RYALTRIS COMPOUND NASAL
SPRAY
SUBMITTED TO NMPA ACCEPTED
Source text for Eikon: ID:n11067132-1
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement